Lasmiditan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Lasmiditan: From Acute Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Lasmiditan (REYVOW™) is a highly selective serotonin 5-HT1F receptor agonist approved by the US FDA in October 2019 for the acute treatment of migraine with or without aura in adults. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura — a rare and historically underserved migraine subtype — with 0 dedicated clinical trials but 18 publications (including systematic reviews and Phase 3 data) currently supporting this direction. The mechanistic rationale is exceptionally strong, as 5-HT1F receptors are densely expressed in the brainstem structures implicated in this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute treatment of migraine with or without aura (US FDA approved, Oct 2019) |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not marketed |
| Number of EU Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Lasmiditan is the first and only approved member of the “ditans” class — a highly selective serotonin 5-HT1F receptor agonist with no meaningful vasoconstrictor activity. Unlike triptans (which act on 5-HT1B/D receptors and cause coronary vasoconstriction), lasmiditan achieves its antimigraine effect by suppressing trigeminal neuron firing and reducing calcitonin gene-related peptide (CGRP) release at the trigeminal nucleus caudalis. Crucially, it crosses the blood-brain barrier and acts centrally.
Migraine with brainstem aura (MBA, formerly called “basilar-type migraine”) is a subtype where aura symptoms originate specifically from the brainstem — dysarthria, vertigo, tinnitus, diplopia, and even transient loss of consciousness. The pathological core of MBA lies precisely in the anatomical region where 5-HT1F receptors are most densely expressed. This makes lasmiditan’s central mechanism of action directly and biologically relevant to MBA, arguably more so than to standard migraine subtypes.
Both pivotal Phase 3 trials (SPARTAN and SAMURAI) enrolled patients with migraine with or without aura without explicitly excluding brainstem aura subtypes. The systematic review by Yang et al. (2020) and network meta-analysis by Polavieja et al. (2022) provide Level 1–2 evidence for lasmiditan’s efficacy across the migraine spectrum, including aura-positive patients. However, no dedicated subgroup analysis for brainstem aura specifically has been published, which is the primary reason this is classified as L2 rather than L1.
Clinical Trial Evidence
Currently no dedicated clinical trials for migraine with brainstem aura have been registered.
The Phase 3 SPARTAN (NCT02605174) and SAMURAI (NCT02439320) trials enrolled broad migraine populations including aura-positive patients, providing indirect evidence. No sub-study or independent Phase 3 trial targeting the brainstem aura subtype is currently registered on ClinicalTrials.gov or ICTRP.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32857291 | 2020 | Systematic Review / Meta-analysis | CNS Drugs | Lasmiditan significantly superior to placebo for 2-hr pain freedom and MBS freedom; FDA-approved at 100 mg and 200 mg; first approved 5-HT1F agonist |
| 35790906 | 2022 | Network Meta-analysis | J Headache Pain | Indirect comparison vs rimegepant and ubrogepant; lasmiditan showed favourable onset-of-efficacy profile in aura-positive subgroups |
| 31132795 | 2019 | Phase 3 RCT | Brain | SPARTAN trial: lasmiditan 50/100/200 mg vs placebo in 3,005 patients including CVD history; all doses met primary endpoints for pain freedom at 2 hr |
| 22459549 | 2012 | Phase 2 RCT | Lancet Neurology | Oral lasmiditan (COL-144) dose-ranging study; demonstrated efficacy and tolerability without vasoconstriction, establishing central 5-HT1F mechanism |
| 33633424 | 2020 | Clinical Review | Psychopharmacology Bulletin | Comprehensive review of lasmiditan for migraine with and without aura; highlights advantage over triptans in cardiovascular-risk patients |
| 36138260 | 2022 | Subgroup Analysis | Advances in Therapy | MONONOFU trial subgroup: lasmiditan efficacy consistent across Japanese patient and migraine characteristics including aura status |
| 32783644 | 2020 | Post hoc Analysis | Curr Med Res Opin | Phase 3 post hoc: lasmiditan efficacy and safety unaffected by common migraine comorbidities (hypertension, diabetes, obesity) |
| 33907459 | 2021 | Case Series | J Pain Research | Migraine with brainstem aura combined with disorders of consciousness: clinical features, pathophysiology at brainstem level; supports 5-HT1F as a rational target |
| 35027572 | 2022 | Review | Nature Rev Disease Primers | Comprehensive migraine primer: cortical spreading depolarization, trigeminal activation, brainstem involvement; situates lasmiditan within current understanding |
| 38024055 | 2023 | Case Report | Cureus | PRES patient with initial visual aura and migraine-like headache showed significant response to lasmiditan; highlights lasmiditan efficacy in complex aura presentations with brainstem involvement |
EU Market Information
Lasmiditan currently holds no EMA marketing authorisation. It is not approved or commercially available in the European Union as of June 2026.
For reference: Lasmiditan received US FDA approval (REYVOW™, Eli Lilly) in October 2019. The drug was not submitted for or did not receive EMA approval during this period. European prescribers do not have access to this molecule through licensed channels.
Safety Considerations
Please refer to the SmPC (or FDA Prescribing Information / REYVOW™ label) for complete safety information, as Taiwan/EU regulatory package data is not available in this evidence pack.
Known from published literature: Lasmiditan is associated with central nervous system side effects including dizziness, somnolence, paraesthesia, and fatigue — consistent with its CNS-penetrant mechanism. The FDA requires patients not drive or operate heavy machinery for at least 8 hours after taking lasmiditan (Schedule V controlled substance in the US due to CNS effects). No vasoconstrictor activity has been demonstrated, making it usable in patients with cardiovascular contraindications to triptans.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Lasmiditan’s mechanism of action (central 5-HT1F agonism at the trigeminal nucleus caudalis and brainstem) is directly aligned with the pathophysiology of migraine with brainstem aura, and Phase 2–3 RCT data from broad migraine populations — including aura-positive patients — provides a credible evidence foundation (L2). The absence of a dedicated brainstem aura subgroup trial is the single largest gap preventing an L1 upgrade.
To proceed, the following is needed:
- Dedicated retrospective subgroup analysis of existing Phase 3 SPARTAN/SAMURAI datasets for brainstem aura patients (IHS criteria: ≥2 brainstem symptoms) — this could be achieved without a new trial
- Prospective Phase 2b or registry study specifically enrolling MBA patients to generate subtype-specific efficacy and safety data
- EU regulatory pathway assessment: lasmiditan has no EMA approval; a full MAA submission (or type-II variation if approved in future) would be required before European use
- Formal MOA documentation from DrugBank API (current data gap) to complete mechanism-of-action cross-validation
- Safety review based on the official SmPC or FDA label — particularly CNS sedation risk profiling for the brainstem aura population, who may have additional neurological vulnerability during attacks
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.